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E-mail: paulm@post.tau.ac.ilAdvances in medicine are accompanied by an ascending toll of
infectious complications. In a previous thematic section we
reviewed the burden of bacteremia, as a marker of severe in-
fections [1]. A population-based incidence rate of bacteremia
ranging between 140 and 160 per 100 000 in high-income
countries was compiled from many studies, making the
burden of bacteremia alone comparable to diseases such as
major stroke, acute myocardial infarction and trauma [2]. In a
systematic review of population-based studies, bacteremia
came out as the ﬁfth to seventh leading cause of death in North
America and several countries in Europe [3]. Although not
counted separately in the Global Burden of Disease, bacteremia
mortality rates of 23.5 to 27.5 per 100 000 person-years in the
USA, bring it above most age-standardized death rates for in-
dividual conditions [4]. Nosocomial bacteremias affect between
2.7 and 8.2 of patients admitted to hospitals in the USA and
Europe, with short-term mortality rates ranging between 12
and 32% of patients [3]. Consequences of bacteremia extend
well beyond the ﬁrst month after infection, with curtailed long-
term survival, impairment in quality of life, cognitive function
and functional capacity [5].
The current theme issue addresses contemporary clinical
and microbiological tools for improving the management of
bacteremia. Rates of appropriate empirical antibiotics for pa-
tients with bacteremia have not improved with time, but rather
decrease with increasing antimicrobial resistance [6,7]. We
need tools to identify infections early on and prescribe covering
and effective antibiotics to those with severe bacterial in-
fections. We need to avoid unruly empirical antibiotics for
patients who do not have severe infections and to avoid anti-
biotic treatment altogether in those who do not have a bacterial
infection. Empirical data showing lower mortality associatedClinical Microbiology and Infection © 2015 European Society of Cwith early covering antibiotics are restricted to patients with
severe infections, mostly with bacteremia [8]. By deﬁnition data
are restricted to patients with microbiologically documented
infections. Implementing the evidence for all patients with
suspected infection results in high rates of unnecessary antibi-
otics. We need better triage of patients with severe bacterial
infections and point-of-care tests for prescribing appropriate
and non-superﬂuous antibiotics to these patients. Here, we
address the promises and disappointments of contemporary
research into improving bloodstream infection diagnosis and
management.
Eliakim-Raz et al. reviewed prediction models for bacteremia
[9]. On the whole, the models performed well. Starting usually
with non-selected patients from whom blood cultures were
drawn, the models could triage patients into substantially sized
low-risk and high-risk groups. In the low-risk group the median
percentage of patients with bacteremia was 2.7% in the deri-
vation cohorts and 2.9% in the validation cohorts (range
0–15%). In the high-risk group bacteremia rates were 35%
(range 14–83%) in the derivation cohorts and 28.5% (range
11–80%) in the validation cohorts. This compares favourably
with physicians’ performance, which was formally assessed in a
single study and a single centre and reported that physicians
markedly overestimated the probability of bacteremia (physi-
cians’ prediction of 16–40% versus actual 4.2%; and physicians’
prediction of 41–99% versus actual 12.2%) [10]. However,
none of the bacteremia prediction studies compared the sug-
gested model to physicians’ performance directly and none
were tested in an interventional clinical study to examine the
effects of the model on patient outcomes, except for a single
model that was tested as part of a more complex decision
support system [11]. Furthermore, through correspondence
with the primary model developers, the authors established
that none of these models are being used in clinical practice.
Hence, prediction models for bacteremia hold promise but
have not been ingrained into clinical practice.
Pogue et al. review methods to improve appropriate
empirical antibiotic treatment in the era of multidrug-resistantClin Microbiol Infect 2015; 21: 291–294
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FIG. 1. Rates of carbapenem-resistance of all Klebsiella pneumoniae
clinical isolates, at Rambam Health Care Campus between 1996 and
2014.
292 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMI(MDR) bacteria [12]. Unlike the bacteremia prediction models,
the models attempting to predict infections caused by MDR
bacteria do not perform particularly well. The authors present
selected models with sensitivity values ranging from 44 to 86%
and speciﬁcities from 41 to 98%, where models with good
sensitivity have poor speciﬁcity and vice versa. DifﬁcultiesClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectencountered in such models include ‘resistance-speciﬁc’ risk
factors that are shared among different MDR species and
‘species-speciﬁc’ risk factors shared between antibiotic-
susceptible and antibiotic-resistant phenotypes of the same
species. Furthermore, implementation of these models requires
that the control population in the original studies mimic the
patient population suspected of infection in clinical practice,
which was not the case with most studies to date. To be useful
in directing antibiotic prescription, the models should predict
both the existence of a severe infection and the MDR pheno-
type. Finally, perhaps the greatest difﬁculty with such models is
that a model is relevant to a speciﬁc epidemiological setting.
Even in the same locale the model cannot remain ﬁxed for long
because there is an epidemic curve of new resistance traits that
depends on many factors. As an example, the epidemic curve of
carbapenem-resistant Klebsiella pneumoniae in one hospital is
shown in Fig. 1 (personal data). A model developed in 2008 in
response to the carbapenem-resistant Klebsiella pneumoniae
outbreak would probably not be relevant a year later. As in the
bacteremia prediction models, the models to predict MDR
bacteria have not been adopted into clinical practice to date.FIG. 2. Usefulness of Gram staining
of positive blood cultures for pre-
sumptive early bacterial identiﬁca-
tion. (a) Gram stain of a blood
culture broth positive for Car-
diobacterium hominis showing typical
pleomorphic Gram-negative bacilli
arranged as rosettes or presenting
teardrop forms; the patient pre-
sented a prosthetic endocarditis. (b)
Gram stain of a positive blood cul-
ture pellet showing the typical aspect
of mycobacteria with heterogeneous
Gram-positive staining. (c) Brown
granules macroscopically visualized in
a positive anaerobic blood culture
bottle taken from a patient suffering
from Aggregatibacter actino-
mycetemcomitans endocarditis. (d)
Gram stain of the blood culture
bottle shown in (c), showing the huge
granules resulting from the aggrega-
tion of Aggregatibacter actino-
mycetemcomitans, a bacterium named
based on its adhesive properties.
(Pictures kindly provided by G
Prod’hom, Lausanne, Switzerland.)
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CMI Editorial 293Another important approach to improve patient manage-
ment is to improve early diagnosis of sepsis and bacteremia. In
the third article of this issue, Opota et al. present the state-of-
the-art on blood cultures, discussing the currently available
broths, the automated systems, and the main issues associated
with pre- and post-analytical aspects [13]. In addition, their
article provides an extended review on the very recent
breakthrough achieved during the last ﬁve years by using blood
culture pellets as starting material to perform rapid matrix-
assisted laser desorption/ionization–time of ﬂight (MALDI-
TOF) identiﬁcation of bacteria. Shortening the time to identi-
ﬁcation of the agents of bloodstream infections by using
MALDI-TOF has a major clinical impact, as demonstrated by
recent studies [14,15]. However, this should not be done at the
cost of accuracy. It is of paramount importance to always
perform a Gram stain concomitantly with the MALDI-TOF, to
detect polymicrobial bacteremias. For instance, in a blood-
stream infection caused by Escherichia coli and enterococci, the
latter are often initially not documented by MALDI-TOF
because of their lower growth rate. Moreover, Gram stain
may provide some valuable phenotypic information suggesting
the bacterial identiﬁcation (Fig. 2), which is especially useful
when the MALDI-TOF does not provide a result (as occurs in
about 10–20% of cases). In this review article, Opota et al. also
underline the usefulness of performing some PCR-based tests,
such as the point-of-care PCR testing for methicillin-resistant
Staphylococcus aureus [16] and biochemical tests to detect
speciﬁc antimicrobial resistance, directly on blood culture
pellets.
In the fourth article of this thematic section, molecular
diagnosis directly applied to blood samples is discussed [17].
The high sensitivity of PCR-based assays allows us to circum-
vent the paucibacterial nature of bloodstream infections, but
low speciﬁcity of such PCR-based assays and PCR inhibitors
present in the blood limit the success of these tests. Moreover,
as mentioned by Opota et al., these PCR-based tests are only a
complement to blood cultures, which remain essential to
provide strains for antibiotic susceptibility testing, and their
costs limit their widespread use.
Should we be disappointed by modelling attempts and aban-
don these? Should we be disappointed by the limitations of
modern diagnostic tools? Perfect diagnostics appear very
attractive from the point of the view of the clinician struggling to
improve antibiotic management of severe infections. A perfect
test would tell the clinician whether the patient has a severe
infection at the point of care, what is its cause and which are the
covering antibiotics. Despite the immense advances in bacterial
diagnostics reviewed in this theme issue, we are still far from
having this perfect diagnostic tool. Current diagnostic ap-
proaches cannot present the complete antibiogram in real timeClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyand genetic testing of resistance does not correlate perfectly with
phenotypic resistance. Moreover, the problem will always
remain that bacteria can cause either colonization or infection,
not all severe infections are bacteraemic and even the docu-
mented presence of bacteria in blood might represent contam-
ination. However, given the well-documented impact of shorter
time to results on adequacy of early antibiotic treatment for
bacteremia, new innovative diagnostic approaches should be
implemented as soon as possible in most hospitals for the beneﬁt
of patient care [14,15]. Similarly, despite the deﬁciencies of
current modelling attempts, models are necessary to place di-
agnostics in the light of other clinical information [18]. The advent
of electronic patient ﬁles in hospitals can make models much
easier to implement than before. Most of the variables needed for
such models are available electronically. Models will probably
need to be much more complex than those reviewed, with op-
tions for local and temporal calibration. Ultimately, the target is
to achieve a much better balance between early appropriate
antibiotic treatment for severe infections and avoidance of su-
perﬂuous and unnecessary antibiotic treatments. Only then will
we be able to curb the resistance slope and improve the man-
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